Abstract
Hypercoagulable testing is an area of clinical medicine fraught with misconception and misunderstanding. We all desire to provide our patients with the best possible diagnosis and understanding of their medical condition. However, laboratory testing for thrombophilia is overused, frequently misunderstood, and in many cases ordered without a good understanding of the results. Laboratory testing for thrombophilia may be affected by many patient-related, therapy-related, and laboratory-related factors. An understanding of these influences will lead to a better understanding of when testing may be warranted. The diagnosis of a thrombophilic state may impact future care and decisions on anticoagulation and periprocedural or peripartum care. In addition, overuse and inappropriately timed hypercoagulable testing can impact the cost of care, length of stay, and immediate as well as long-term anticoagulation decisions. The savvy practitioner should seek to gain an understanding of the pearls and pitfalls of thrombophilia testing. This chapter will strive to help determine the optimal tests, timing of testing, and impact of hypercoagulable testing for patients with venous and arterial thromboembolism.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Society of Hematology. Ten Things Physicians and Patients Should Question. http://www.choosingwisely.org/societies/american-society-of-hematology/.
Mannucci PM, Franchini M. Classic thrombophilic gene variants. Thromb Haemost. 2015;114:885–9.
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464–74.
Morange PE, Tregouet DA. Current knowledge on the genetics of incident venous thromboembolism. J Thromb Haemost. 2013;11(suppl 1):111–21.
Heit JA, Ashrani A, Crusan DJ, McBane RD, Petterson TM, Bailey KR. Reasons for the persistent incidence of venous thromboembolism. Thromb Haemost. 2017;117(2):390–400.
Heit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41:3–14.
Khor B, Van Cott EM. Laboratory testing for antithrombin deficiency. Am J Hematol. 2010;85:947–50.
Khor B, Van Cott EM. Laboratory tests for protein C deficiency. Am J Hematol. 2010;85:440–2.
Eby C. Laboratory aspects of Thrombophilia testing. In: Kotte-Marchant K, editor. An algorithmic approach to hemostasis testing. Northfield: College of American Pathologists (CAP); 2008.
Marlar RA, Gausman JN. Protein S abnormalities: a diagnostic nightmare. Am J Hematol. 2011;86:418–21.
Van Cott EM, Khor B, Zehnder JL. Factor V Leiden. Am J Hematol. 2016;91:46–9.
Kadauke S, Khor B, Van Cott EM. Activated protein C resistance testing for factor V Leiden. Am J Hematol. 2014;89:1147–50.
Castaman G, Faioni EM, Tosetto A, Bernardi F. The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica. 2003;88:1182–9.
Cosmi B, Legnani C, Cini M, Favaretto E, Palareti G. D-dimer and factor FVIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res. 2008;122:610–7.
Jenkins VP, Rawley O, Smith OP, O’Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br J Haematol. 2012;157:653–66.
Cushman M, O’Meara ES, Folsom AR, Heckbert SR. Coagulation facotes IX through XIII and the risk of future venous thrombosis: the longitudinal investigation of thromboembolism etiology. Blood. 2009;114:2878–83.
Key NS. Epidemiology and clinical data linking factors XI and XII to thrombosis. Hematology Am Soc Hematol Educ Program. 2014;2104(1):66–70.
Casini A, Neerman-Arbex M, Ariens RA, De Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13:909–19.
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid antibody syndrome (APS). J Thromb Haemost. 2006;4:295–306.
Salmon JE, de Groot PG. Pathogenic role of antiphospholipid antibodies. Lupus. 2008;17:405–11.
Chaturvedi S, McCrae KR. The antiphospholipid syndrome still an enigma. Hematology Am Soc Hematol Educ Program. 2015;2015:53–60.
Giannakopoulos B, Passam F, Ioannou Y, Krillis SA. How we diagnosis the antiphospholipid syndrome. Blood. 2009;113:985–94.
Giannakopoulos B, Passam F, Soheila R, Krillis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109:422–30.
MaIntyre JA, Wagenknech DR, Waxman DW. Frequency and specificities if antiphospholipid antibodies (aPL) in volunteer blood donors. Immunobiology. 2003;207:59–63.
Franchini M, Martinelli I, Mannucci PM. Uncertain thrombophilia markers. Thromb Haemost. 2016;115:25–30.
Eldibany MM, Caprini JA. Hyperhomocysteinemia and thrombosis: an overview. Arch Pathol Lab Med. 2007;131:872.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Carman, T.L. (2018). Thrombophilia Testing. In: Lau, J., Barnes, G., Streiff, M. (eds) Anticoagulation Therapy . Springer, Cham. https://doi.org/10.1007/978-3-319-73709-6_16
Download citation
DOI: https://doi.org/10.1007/978-3-319-73709-6_16
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73708-9
Online ISBN: 978-3-319-73709-6
eBook Packages: MedicineMedicine (R0)